Recent Publications from the Kumar-Singh Lab

Research Publications Cell Biology Genetics Immunology
Neuroscience

 

Dasari BC, Cashman SM, Kumar-Singh R. 2017. Reducible PEG-POD/DNA nanoparticles for gene transfer in vitro and in vivo: Application in a mouse model of age-related macular degeneration. Mol Ther Nucelic Acids 8: 77-89.  Abstract in PubMed

Leaderer D, Cashman SM, Kumar-Singh R. 2016. G-quartet oligonucleotide mediated delivery of proteins into photoreceptors and retinal pigment epithelium via intravitreal injection. Exp Eye Res. 145: 380-392.   Abstract in PubMed

Leaderer D, Cashman SM, Kumar-Singh R. 2015. Topical application of a G-quartet aptamer targeting nucleolin attenuates choroidal neovascularization in a model of age-related macular degeneration. Exp Eye Res. 140: 171-178.   Abstract in PubMed

Cashman SM, Gracias J, Adhi M, Kumar-Singh R. 2015. Adenovirus mediated delivery of factor H attenuates complement C3 induced pathology in the murine retina: a potential gene therapy for AMD. J Gen Med. 17: 229-243.   Abstract in PubMed

Leaderer D, Cashman SM, Kumar-Singh R. 2015. Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59. J Gene Med. 17: 101-115. Abstract in PubMed

Kwong JM, Gu L, Nassiri N, Bekerman V, Kumar-Singh R, Rhee KD, Yang XJ, Hauswirth WW, Caprioli J, Piri N. 2014. AAV-mediated and pharmacological induction of Hsp70 expression stimulates survival of retinal ganglion cells following axonal injury. Gene Ther. 22: 138-145. Abstract in PubMed

Jin SX, Bartolome C, Arai JA, Hoffman L, Uzturk BG, Kumar-Singh R, Waxham MN, Feig LA. 2014. Domain contributions to signaling specificity differences between Ras-Guanine Nucleotide Releasing Factor (Ras-GRF)1 and Ras-GRF2. J Biol Chem. 289: 16551-16564. Abstract in PubMed

Birke MT, Lipo E, Adhi M, Birke K, Kumar-Singh R. 2014. AAV-mediated expression of human PRELP inhibits complement activation, choroidal neovascularization and deposition of membrane attack complex in mice. Gene Ther. 21: 507-513. Abstract in PubMed

Binder C, Cashman SM, Kumar-Singh R. 2013. Extended duration of transgene expression from pegylated POD nanoparticles enables attenuation of photoreceptor degeneration. PLoS One 8: e82295. Abstract in PubMed

Adhi M, Cashman SM, Kumar-Singh R. 2013. Adeno-associated virus mediated delivery of a non-membrane targeted human soluble CD59 attenuates some aspects of diabetic retinopathy in mice. PLoS One 8: e79661. Abstract in PubMed

Birke K, Lipo E, Birke MT, Kumar-Singh R. 2013. Topical application of PPADS inhibits complement activation and choroidal neovascularization in a model of age-related macular degeneration. PLoS One 8: e76766. Abstract in PubMed

Lipo EK, Cashman S, Kumar-Singh R. 2013. Aurintricarboxylic acid inhibits complement activation, membrane attack complex and choroidal neovascularization in a model of macular degeneration. Invest Ophthalmol Vis Sci. 54: 7107-7114.  Abstract in PubMed

Jin SX, Arai J, Tian X, Kumar-Singh R, Feig LA. 2013. Acquisition of contextual discrimination involves the appearance of a Ras-GRF1/p38 map kinase-mediated signaling pathway that promotes LTP. J Biol Chem. 288: 21703-21713. Abstract in PubMed

Greenwald DL, Cashman SM, Kumar-Singh R. 2013. Mutation-independent rescue of a novel mouse model of Retinitis Pigmentosa. Gene Ther. 20: 425-434. books

Gandhi J, Cashman SM, Kumar-Singh R. 2011. Soluble CD59 expressed from an adenovirus in vivo is a potent inhibitor of complement deposition on murine liver vascular endothelium. PLoS One. 6: e21621. books

Cashman SM, Ramo K, Kumar-Singh R. 2011. A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration. PLoS One. 6: e19078. books

Cashman SM, Desai A, Ramo K, Kumar-Singh R. 2011. Expression of complement component 3 (C3) from an adenovirus leads to pathology in the murine retina. Invest Ophthalmol Vis Sci. 52: 3436-3445.  books

Binder C, Cashman, SM, Read, SP, Kumar-Singh, R. 2011. Nuclear targeted delivery of macromolecules to retina and cornea. J Gene Med. 13: 158-170. books

Sweigard JH, Cashman SM, Kumar-Singh R. 2011. Adenovirus-mediated delivery of CD46 attenuates the alternative complement pathway on RPE: implications for age-related macular degeneration. Gene Ther. 18: 613-621. books

Read SP, Cashman SM, Kumar-Singh R. 2010. POD nanoparticles expressing GDNF provide structural and functional rescue of light-induced retinal degeneration in an adult mouse. Mol Ther. 18: 1917-1926. books

Ma KN, Cashman SM, Sweigard JH, Kumar-Singh R. 2010. Decay accelerating factor (CD55)-mediated attenuation of complement: therapeutic implications for age-related macular degeneration. Invest Ophthalmol Vis Sci. 51: 6776-6783. books

Greenwald DL, Cashman SM, Kumar-Singh R. 2010. Engineered zinc finger nuclease-mediated homologous recombination of the human rhodopsin gene. Invest Ophthalmol Vis Sci. 51: 6374-6380. books

Parker Read S, Cashman SM, Kumar-Singh R. 2010. A poly(ethylene) glycolylated peptide for ocular delivery compacts DNA into nanoparticles for gene delivery to post-mitotic tissues in vivo. J Gene Med. 12: 86-96. books

Read SP, Cashman SM, Kumar-Singh R. 2010. Gene-based Therapy in Ocular Angiogenesis. In: Therapy of Ocular Angiogenesis: Principles & Practice, Das A and Friberg T, eds, Lippincott Williams & Wilkins, Chapter 15.

Sweigard JH, Cashman S, Kumar-Singh R. 2009. Adenovirus vectors targeting distinct cell types in the retina. Invest Ophthalmol Vis Sci. 51: 2219-2228. books

Johnson, LN, Cashman SM, Read SP, Kumar-Singh R. 2009. Cell penetrating peptide POD mediates delivery of recombinant proteins to retina, cornea and skin. Vision Res. 50: 686-697. books

Johnson LA, Cashman S,  Kumar-Singh R. 2008. Cell penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea.  Mol Ther. 16: 107-114. books

Ramo K, Cashman S, Kumar-Singh R. 2008. Evaluation of adenovirus-delivered human CD59 as a potential therapy for AMD in a model of human membrane attack complex formation on murine RPE. Invest Ophthalmol Vis Sci. 9: 4126-4136. books

Kumar-Singh R. 2008. Barriers for retinal gene therapy: Separating fact from fiction.  Vision Res. 48: 1671-1680. books

Cashman S, McCullough L, Kumar-Singh R.  2007. Improved retinal transduction in vivo and photoreceptor-specific transgene expression using adenovirus vectors with modified penton base. Mol Ther. 15: 1640-1646. books

Menotti-Raymond M, David VA, Schaffer AA, Stephens R, Wells D, Kumar-Singh R, O’Brien SJ, Narfstrom K. 2007. Mutation in CEP290 discovered for cat model of human retinal degeneration. J Hered. 98: 211-220. books

Cashman,S., Bowman, L, Christofferson, J. and Kumar-Singh, R. 2006. Inhibition of choroidal neovascularization by adenovirus mediated delivery of short hairpin RNAs targeting VEGF as a potential therapy for AMD. Invest Ophthalmol Vis Sci. 47: 3496-3504. books

Cashman SM, Binkley EA, Kumar-Singh R. 2005. Towards mutation-independent silencing of genes involved in retinal degeneration by RNA interference. Gene Ther. 12: 1223-1228. books

Cashman S, Morris D, Kumar-Singh R. 2004. Adenovirus type 5 pseudotyped with adenovirus type 37 fiber uses sialic acid as a cellular receptor. Virology 324: 129-139. books

Apply to the Sackler School

apply

The priority application deadlines are as follows:

December 1: Basic Science Division PhD Programs

February 15: Building Diversity in Biomedical Sciences

March 31: Post-Baccalaureate Research Program

May 1: Clinical & Translational Science, MS in Pharmacology & Drug Development

June 15: Online Certificate in Fundamentals of Clinical Care Research